• Policy
• Madopar triggers bioequivalence test verification requests
• by Lee, Hye-Kyung Sep 26, 2023 05:50am

• Policy
• Pfizer’s Bosulif in pricing negotiations for reimb in KOR
• by Lee, Tak-Sun Sep 26, 2023 05:49am

• Policy
• Hanmi is the first to release Zytiga generic at half price
• by Lee, Tak-Sun Sep 25, 2023 05:35am

• Policy
• Mifegyne, inadequate national essential drug system
• by Lee, Jeong-Hwan Sep 25, 2023 05:34am

• Policy
• Vabysmo·Evrysdi will be reimbursed in October
• by Lee, Jeong-Hwan Sep 25, 2023 05:34am

• Policy
• How Samsung’s biosimilar became covered in the US
• by Lee, Hye-Kyung Sep 22, 2023 05:41am

• Policy
• Vabysmo·Evrysdi, listed as reimbursement
• by Lee, Tak-Sun Sep 22, 2023 05:41am

• Policy
• Bioequivalence reevals speed up in line with drug price reev
• by Lee, Hye-Kyung Sep 21, 2023 05:24am

• Policy
• Pseudoephedrine price negotiations have been concluded
• by Lee, Tak-Sun Sep 21, 2023 05:24am

• Policy
• ‘Introduce a Korean Cancer Moonshot Plan for patients'
• by Lee, Jeong-Hwan Sep 21, 2023 05:24am